HYPERTENSIVE OPTIC NEUROPATHY AS A PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS A CASE REPORT

Main Article Content

Lia Meuthia Zaini, dr. http://orcid.org/0000-0003-2352-7131 Putri Nabillah Mulya http://orcid.org/0000-0001-5468-5568

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems, including the eyes. Hypertensive optic neuropathy is a rare but serious manifestation of SLE that may precede SLE diagnosis. This case highlights the early ocular involvement in a young patient with undiagnosed SLE.


Case Report: A 21-year-old female presented to our ophthalmology clinic with blurry vision in both eyes, along with elevated blood pressure at 165/126 mmHg. Ophthalmic examination revealed visual acuity of 20/200 on both eyes, bilateral optic disc swelling, macular edema, flame-shaped hemorrhages, and cotton-wool spots. These findings are consistent with hypertensive optic neuropathy. The antihypertensive drugs were initiated and planned for intravitreal bevacizumab administration. The patient was referred to internal medicine. Laboratory tests and clinical findings indicated secondary hypertension, anemia, leukopenia, and thrombocytopenia. Immuno-serological testing confirmed a diagnosis of SLE. The patient was initiated on systemic immunosuppressive therapy. Eight weeks after the first visit, she showed significant improvement, with the resolution of macular edema and optic disc swelling. The patient’s visual acuity improved to 20/50 in the right eye (RE) and 20/20 in the left eye (LE).


Discussion: Hypertension in SLE is multifactorial, involving endothelial dysfunction, kidney injury, immune activation, and autoantibodies. Hypertensive retinopathy progresses through three phases: vasoconstrictive, sclerotic, and exudative, characterized by arterial narrowing, structural vascular changes, and blood-retina barrier disruption, leading to macular edema and ischemia. Diagnosis is based on fundoscopic examination and Optical Coherence Tomography (OCT), while management focuses on blood pressure control, anti-VEGF therapy, and close monitoring to prevent further complications.


Conclusion: Early detection and multidisciplinary management are crucial in preventing irreversible visual loss and systemic complications. Regular ophthalmic follow-up and blood pressure monitoring are essential in SLE management.

Keywords

hypertensive optic neuropathy, hypertensive retinopathy, macular edema, lupus nephritis, systemic lupus erythematosus, anti-VEGF

Article Details

How to Cite
ZAINI, Lia Meuthia; MULYA, Putri Nabillah. HYPERTENSIVE OPTIC NEUROPATHY AS A PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS. International Journal of Retina, [S.l.], v. 8, n. 2, sep. 2025. ISSN 2614-8536. Available at: <https://ijretina.com/index.php/ijretina/article/view/323>. Date accessed: 28 oct. 2025. doi: https://doi.org/10.35479/ijretina.2025.vol008.iss002.323.
Section
Case Report

References

1. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‐Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2019;71:1400–12.
2. Dammacco R, Procaccio P, Racanelli V, Vacca A, Dammacco F. Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers. Ocul Immunol Inflamm. 2018;26:1154–65.
3. de Andrade FA, Guimarães Moreira Balbi G, Bortoloti de Azevedo LG, Provenzano Sá G, Vieira de Moraes Junior H, Mendes Klumb E, et al. Neuro-ophthalmologic manifestations in systemic lupus erythematosus. Lupus. 2017;26:522–8.
4. Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. British Journal of Ophthalmology. 2016;100:135–41.
5. Jaryal A, Vikrant S. Current status of lupus nephritis. Indian Journal of Medical Research. 2017;145:167–78.
6. Seth G, Chengappa KG, Misra DP, Babu R, Belani P, Shanoj KC, et al. Lupus retinopathy: a marker of active systemic lupus erythematosus. Rheumatol Int. 2018;38:1495–501.
7. Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, Mediavilla JD, Jiménez-Jáimez J, Antonio Díaz-Chamorro, et al. Prevalence of and Factors Associated with Hypertension in Young and Old Women with Systemic Lupus Erythematosus. J Rheumatol. 2011;38:1026–32.
8. Taylor EB, Wolf VL, Dent E, Ryan MJ. Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol. 2019;176:1897–913.
9. McClung DM, Kalusche WJ, Jones KE, Ryan MJ, Taylor EB. Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus. Physiol Rep. 2021;9.
10. Tsukikawa M, Stacey AW. A Review of Hypertensive Retinopathy and Chorioretinopathy. Clin Optom (Auckl). 2020;Volume 12:67–73.
11. Luboń W, Luboń M, Kotyla P, Mrukwa-Kominek E. Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature. Int J Mol Sci. 2022;23:12264.
12. Dziedziak J, Zaleska-Żmijewska A, Szaflik JP, Cudnoch-Jędrzejewska A. Impact of Arterial Hypertension on the Eye: A Review of the Pathogenesis, Diagnostic Methods, and Treatment of Hypertensive Retinopathy. Med Sci Monit. 2022;28:e935135.
13. Haydinger CD, Ferreira LB, Williams KA, Smith JR. Mechanisms of macular edema. Front Med (Lausanne). 2023;10.
14. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.
15. El-Mayah E, Mahmoud BMS, Abdelaziz MS, Kotb MS. Retinal and optic nerve microvasculature assessment in nephritic and nonnephritic systemic lupus erythematosus: a comparative analysis. Delta Journal of Ophthalmology. 2024;25:219–28.